关注
Xiaomeng Hu
Xiaomeng Hu
Principal Scientist, Sana Biotechnology
在 sana.com 的电子邮件经过验证
标题
引用次数
引用次数
年份
Hypoimmunogenic derivatives of induced pluripotent stem cells evade immune rejection in fully immunocompetent allogeneic recipients
T Deuse, X Hu, A Gravina, D Wang, G Tediashvili, C De, WO Thayer, ...
Nature biotechnology 37 (3), 252-258, 2019
5722019
The SIRPα–CD47 immune checkpoint in NK cells
T Deuse, X Hu, S Agbor-Enoh, MK Jang, M Alawi, C Saygi, A Gravina, ...
Journal of Experimental Medicine 218 (3), e20200839, 2021
1082021
De novo mutations in mitochondrial DNA of iPSCs produce immunogenic neoepitopes in mice and humans
T Deuse, X Hu, S Agbor-Enoh, M Koch, MH Spitzer, A Gravina, M Alawi, ...
Nature Biotechnology 37 (10), 1137-1144, 2019
942019
SCNT-derived ESCs with mismatched mitochondria trigger an immune response in allogeneic hosts
T Deuse, D Wang, M Stubbendorff, R Itagaki, A Grabosch, LC Greaves, ...
Cell Stem Cell 16 (1), 33-38, 2015
752015
Hypoimmune induced pluripotent stem cells survive long term in fully immunocompetent, allogeneic rhesus macaques
X Hu, K White, AG Olroyd, R DeJesus, AA Dominguez, WE Dowdle, ...
Nature biotechnology 42 (3), 413-423, 2024
402024
Human hypoimmune primary pancreatic islets avoid rejection and autoimmunity and alleviate diabetes in allogeneic humanized mice
X Hu, C Gattis, AG Olroyd, AM Friera, K White, C Young, R Basco, ...
Science translational medicine 15 (691), eadg5794, 2023
302023
Hypoimmune induced pluripotent stem cell–derived cell therapeutics treat cardiovascular and pulmonary diseases in immunocompetent allogeneic mice
T Deuse, G Tediashvili, X Hu, A Gravina, A Tamenang, D Wang, ...
Proceedings of the National Academy of Sciences 118 (28), e2022091118, 2021
302021
Hypoimmune anti-CD19 chimeric antigen receptor T cells provide lasting tumor control in fully immunocompetent allogeneic humanized mice
X Hu, K Manner, R DeJesus, K White, C Gattis, P Ngo, C Bandoro, ...
Nature Communications 14 (1), 2020, 2023
262023
A cryoinjury model to study myocardial infarction in the mouse
D Wang, G Tediashvili, X Hu, A Gravina, SG Marcus, H Zhang, JE Olgin, ...
JoVE (Journal of Visualized Experiments), e59958, 2019
92019
The HY antigen in embryonic stem cells causes rejection in syngeneic female recipients
X Hu, ST Kueppers, NG Kooreman, A Gravina, D Wang, G Tediashvili, ...
Stem Cells and Development 29 (18), 1179-1189, 2020
72020
Hypoimmune islets achieve insulin independence after allogeneic transplantation in a fully immunocompetent non-human primate
X Hu, K White, C Young, AG Olroyd, P Kievit, AJ Connolly, T Deuse, ...
Cell Stem Cell 31 (3), 334-340. e5, 2024
52024
Engineered hypoimmune allogeneic CAR T cells exhibit innate and adaptive immune evasion even after sensitization in humanized mice and retain potent anti-tumor activity
X Hu, M Dao, K White, C Gattis, R Clarke, S Landry, R Basco, E Tham, ...
Blood 138, 1690, 2021
52021
Thalidomide treatment prevents chronic graft rejection after aortic transplantation in rats–an experimental study
KK Miller, D Wang, X Hu, X Hua, T Deuse, E Neofytou, T Renne, J Velden, ...
Transplant International 30 (11), 1181-1189, 2017
52017
Abstract LB144: overexpression of CD47 protects hypoimmune CAR T cells from innate immune cell killing
X Hu, M Dao, K White, R Clarke, S Landry, R Basco, C Gattis, E Tham, ...
Cancer Research 81 (13_Supplement), LB144-LB144, 2021
42021
Hypoimmune, allogeneic CD22-directed CAR T cells that evade innate and adaptive immune rejection for the treatment of large B cell lymphoma patients that are relapsed …
A Johnson, H Wright, X Hu, J Kinder, N van Hoeven, O Liang, B Granger, ...
Blood 142, 3437, 2023
22023
Phase 1 study of SC291, a hypoimmune, allogeneic CD19-directed CAR T cell therapy for relapsed/refractory B-cell malignancies (ARDENT)-initial clinical data
SS Neelapu, LE Budde, JP McGuirk, S Dahiya, A Deol, PA Thompson, ...
Blood 142, 6852, 2023
22023
Development of a novel, allogeneic GPRC5D-directed CAR for treatment of multiple myeloma patients
J Kinder, CA Estrada, B Granger, A O'Rourke, O Liang, A Lampano, ...
Blood 142, 3290, 2023
12023
A dual-antigen targeting, hypoimmune allogeneic CAR T to evade innate and adaptive immune rejection and overcome antigen escape
A Johnson, H Wright, X Hu, B Granger, O Liang, J Moreno, M Lamba, ...
Blood 140 (Supplement 1), 4552-4553, 2022
12022
Engineered hypoimmune allogeneic CAR T cells as potential off-the-shelf CAR T cell immunotherapies
X Hu, K White, C Gattis, R Clarke, S Landry, R Basco, E Tham, E Luo, ...
Cancer Research 82 (12_Supplement), 5598-5598, 2022
12022
Generation of Hypoimmunogenic Induced Pluripotent Stem Cells for Allogeneic Cell and Tissue Transplantation
X Hu, T Deuse, N Kooremann, A Malik, D Wang, G Tediashvili, J Velden, ...
Transplantation 101 (5S-3), S2, 2017
12017
系统目前无法执行此操作,请稍后再试。
文章 1–20